ULBP1 antibody (AA 26-216) (Biotin)
Quick Overview for ULBP1 antibody (AA 26-216) (Biotin) (ABIN7174679)
Target
See all ULBP1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 26-216
-
Cross-Reactivity
- Human
-
Purification
- >95%, Protein G purified
-
Immunogen
- Recombinant Human UL16-binding protein 1 protein (26-216AA)
-
Isotype
- IgG
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4 -
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C,-80 °C
-
Storage Comment
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
- ULBP1 (UL16 Binding Protein 1 (ULBP1))
-
Alternative Name
- ULBP1
-
Background
-
Background: Ligand for the KLRK1/NKG2D receptor, together with at least ULBP2 and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to KLRK1/NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. In CMV infected cells, interacts with soluble CMV glycoprotein UL16. The interaction with UL16 blocked the interaction with the KLRK1/NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP1 to be retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface.
Aliases: Alcan beta antibody, ALCAN-beta antibody, N2DL-1 antibody, N2DL1 antibody, N2DL1_HUMAN antibody, NKG2D ligand 1 antibody, NKG2D ligand 1 precursor antibody, NKG2DL1 antibody, RAET1I antibody, Retinoic acid early transcript 1I antibody, UL16 antibody, UL16 binding protein 1 antibody, UL16-binding protein 1 antibody, ULBP1 antibody
-
UniProt
- Q9BZM6
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process
Target
-